Sarepta Therapeutics Inc (SRPT)
123.24
-0.05
(-0.04%)
USD |
NASDAQ |
Nov 04, 13:01
Sarepta Therapeutics Net Income (Quarterly): 6.46M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 6.46M |
| March 31, 2024 | 36.12M |
| December 31, 2023 | 45.66M |
| September 30, 2023 | -40.94M |
| June 30, 2023 | -23.94M |
| March 31, 2023 | -516.76M |
| December 31, 2022 | -109.24M |
| September 30, 2022 | -257.74M |
| June 30, 2022 | -231.48M |
| March 31, 2022 | -105.02M |
| December 31, 2021 | -121.98M |
| September 30, 2021 | -48.14M |
| June 30, 2021 | -81.40M |
| March 31, 2021 | -167.25M |
| December 31, 2020 | -189.32M |
| September 30, 2020 | -196.50M |
| June 30, 2020 | -150.82M |
| March 31, 2020 | -17.49M |
| December 31, 2019 | -235.70M |
| September 30, 2019 | -126.33M |
| June 30, 2019 | -276.40M |
| March 31, 2019 | -76.64M |
| December 31, 2018 | -140.90M |
| September 30, 2018 | -76.39M |
| June 30, 2018 | -109.27M |
| Date | Value |
|---|---|
| March 31, 2018 | -35.36M |
| December 31, 2017 | -24.00M |
| September 30, 2017 | -47.73M |
| June 30, 2017 | -63.05M |
| March 31, 2017 | 84.09M |
| December 31, 2016 | -88.45M |
| September 30, 2016 | -56.74M |
| June 30, 2016 | -62.30M |
| March 31, 2016 | -59.77M |
| December 31, 2015 | -64.68M |
| September 30, 2015 | -51.94M |
| June 30, 2015 | -41.85M |
| March 31, 2015 | -61.56M |
| December 31, 2014 | -44.42M |
| September 30, 2014 | -29.23M |
| June 30, 2014 | -33.87M |
| March 31, 2014 | -28.27M |
| December 31, 2013 | -8.82M |
| September 30, 2013 | -42.03M |
| June 30, 2013 | -19.05M |
| March 31, 2013 | -42.08M |
| December 31, 2012 | -62.07M |
| September 30, 2012 | -49.55M |
| June 30, 2012 | 8.038M |
| March 31, 2012 | -17.70M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-516.76M
Minimum
Mar 2023
45.66M
Maximum
Dec 2023
-126.61M
Average
-109.24M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| Regenxbio Inc | -52.99M |
| Catalyst Pharmaceuticals Inc | 40.79M |
| Vertex Pharmaceuticals Inc | -3.594B |
| Entrada Therapeutics Inc | 55.03M |
| Edgewise Therapeutics Inc | -31.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 362.93M |
| Total Expenses (Quarterly) | 363.63M |
| EPS Diluted (Quarterly) | 0.07 |
| Enterprise Value | 11.52B |
| Gross Profit Margin (Quarterly) | 87.73% |
| Profit Margin (Quarterly) | 1.78% |
| Earnings Yield | 0.60% |
| Operating Earnings Yield | 0.32% |
| Normalized Earnings Yield | 0.8996 |